JP2020513243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513243A5 JP2020513243A5 JP2019529896A JP2019529896A JP2020513243A5 JP 2020513243 A5 JP2020513243 A5 JP 2020513243A5 JP 2019529896 A JP2019529896 A JP 2019529896A JP 2019529896 A JP2019529896 A JP 2019529896A JP 2020513243 A5 JP2020513243 A5 JP 2020513243A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- cell
- immune cells
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104666A JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023172588A JP7885190B2 (ja) | 2016-12-05 | 2023-10-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430263P | 2016-12-05 | 2016-12-05 | |
| US62/430,263 | 2016-12-05 | ||
| PCT/US2017/064507 WO2018106595A1 (en) | 2016-12-05 | 2017-12-04 | Compositions and methods for immune cell modulation in adoptive immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104666A Division JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513243A JP2020513243A (ja) | 2020-05-14 |
| JP2020513243A5 true JP2020513243A5 (cg-RX-API-DMAC10.html) | 2020-08-13 |
| JP7098615B2 JP7098615B2 (ja) | 2022-07-11 |
Family
ID=62491299
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529896A Active JP7098615B2 (ja) | 2016-12-05 | 2017-12-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2022104666A Pending JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023172588A Active JP7885190B2 (ja) | 2016-12-05 | 2023-10-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104666A Pending JP2022130607A (ja) | 2016-12-05 | 2022-06-29 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023172588A Active JP7885190B2 (ja) | 2016-12-05 | 2023-10-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11932870B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3548049A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7098615B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018106595A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3600357A4 (en) * | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| US12036241B2 (en) | 2017-07-19 | 2024-07-16 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CA3082575A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| US20200040056A1 (en) * | 2018-05-31 | 2020-02-06 | Washington University | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies |
| BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
| EP3835416A4 (en) * | 2018-08-10 | 2022-06-08 | Eutilex Co., Ltd. | METHOD FOR THE PREPARATION AND CRYOPRESERVATION OF CD8+ T CELLS SPECIFIC FOR A CANCER ANTIGEN |
| CN112888786A (zh) * | 2018-09-07 | 2021-06-01 | Sotio有限责任公司 | 与调节细胞内乳酸浓度的反式代谢分子组合的嵌合受体多肽及其治疗用途 |
| CA3114385A1 (en) * | 2018-10-05 | 2020-04-09 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| AU2019377461A1 (en) * | 2018-11-06 | 2021-05-27 | Washington University | Chimeric antigen receptor memory-like (CARML) NK cells and methods of making and using same |
| IL330104A (en) | 2019-03-11 | 2026-08-01 | Deciphera Pharmaceuticals Llc | Crystalline forms of rifatinib |
| CN110157680A (zh) * | 2019-05-08 | 2019-08-23 | 浙江大学 | 提高嵌合抗原受体t细胞疗效和作用持久性的细胞培养方法 |
| CN112300997A (zh) * | 2019-08-01 | 2021-02-02 | 上海赛比曼生物科技有限公司 | 通用型car-t细胞及其制备和应用 |
| US12691108B2 (en) | 2019-08-12 | 2026-07-28 | Deciphera Pharmaceuticals, Llc | Methods for treating vascular malformations |
| HRP20260411T1 (hr) | 2019-08-12 | 2026-05-08 | Deciphera Pharmaceuticals, Llc | Ripretinib za liječenje gastrointestinalnih stromalnih tumora |
| JP2022554217A (ja) * | 2019-10-23 | 2022-12-28 | ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ | 養子免疫療法 |
| KR102300846B1 (ko) * | 2019-11-01 | 2021-09-09 | 서울대학교산학협력단 | 면역 활성 개선용 조성물 및 이의 방법 |
| FI4084779T3 (fi) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| WO2021222479A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| AU2022209191A1 (en) * | 2021-01-12 | 2023-07-06 | The Scripps Research Institute | Small molecules for reprograming anti-tumor immunity of t cells |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4071248A1 (en) | 2021-04-07 | 2022-10-12 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Means and methods for enhancing receptor-targeted gene transfer |
| EP4519418A1 (en) * | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| EP4636093A1 (en) * | 2024-04-19 | 2025-10-22 | Paul-Ehrlich-Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel | Targeting mapk-erk pathway for enhancing nucleic acid delivery |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003455C (en) | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| HK1048302A1 (zh) | 1999-08-13 | 2003-03-28 | 大正制药株式会社 | 前列腺素衍生物 |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040175373A1 (en) | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050075276A1 (en) | 2003-03-14 | 2005-04-07 | Christopher Rudd | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| TWI441637B (zh) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Mek雜環抑制劑及其使用方法 |
| WO2007103901A2 (en) | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| CA2657227A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
| GB2444853B (en) | 2006-12-14 | 2010-02-24 | Medical Res Council | Methods & uses |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| AU2009322346B2 (en) | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
| EP2375897A4 (en) | 2009-01-14 | 2013-05-15 | Health Research Inc | METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| EP3789487A1 (en) * | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| RS61406B1 (sr) | 2014-06-06 | 2021-03-31 | Bluebird Bio Inc | Poboljšane kompozicije t ćelija |
| EP3191126B1 (en) * | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2974903A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| CA2980592A1 (en) * | 2015-03-27 | 2016-10-06 | Nantkwest, Inc. | Nk-92 cells in combination therapy with cancer drugs |
| HK1247958A1 (zh) | 2015-05-05 | 2018-10-05 | 菲特治疗公司 | T淋巴细胞的调节 |
| CN107849102B (zh) * | 2015-05-15 | 2022-05-13 | 希望之城 | 嵌合抗原受体组合物 |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3638775A1 (en) * | 2017-06-13 | 2020-04-22 | Fate Therapeutics, Inc. | Compositions and methods for inducing myeloid suppressive cells and use thereof |
-
2017
- 2017-12-04 US US16/466,265 patent/US11932870B2/en active Active
- 2017-12-04 WO PCT/US2017/064507 patent/WO2018106595A1/en not_active Ceased
- 2017-12-04 JP JP2019529896A patent/JP7098615B2/ja active Active
- 2017-12-04 EP EP17879179.4A patent/EP3548049A4/en active Pending
-
2022
- 2022-06-29 JP JP2022104666A patent/JP2022130607A/ja active Pending
-
2023
- 2023-10-04 JP JP2023172588A patent/JP7885190B2/ja active Active
-
2024
- 2024-02-14 US US18/441,709 patent/US20240263135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250215396A1 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| US20240263135A1 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| US12419870B2 (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
| CN109415699B (zh) | Cd4cd8双阳性t细胞的制备方法 | |
| JP2024123210A (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP2022078215A (ja) | 多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法 | |
| JP7668781B2 (ja) | 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法 | |
| JP7747352B2 (ja) | 操作されたガンマデルタt細胞ならびにその作製方法および使用方法 | |
| AU2016344779A1 (en) | Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells | |
| CN119256076A (zh) | 用于产生调节性t细胞的方法 | |
| WO2022059780A1 (ja) | iPS細胞を介する再生T細胞の製造方法 | |
| HK40092133A (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies |